Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: Results of a pooled analysis of non-interventional studies
European Journal of Cancer2015Vol. 51(16), pp. 2368–2374
Citations Over TimeTop 10% of 2015 papers
Laurence Albigès, Ulrich Kube, Jean‐Christophe Eymard, Manuela Schmidinger, Aristotelis Bamias, Nadia Kelkouli, Bernhard Mraz, Styliani Florini, Gernot Guderian, Agnese Cattaneo, Lothar Bergmann
Related Papers
- → Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma(2011)125 cited
- → Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib(2010)16 cited
- → First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC).(2010)14 cited
- → A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma(2014)13 cited
- → Re: Economic Evaluation of Everolimus Versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma After Failure of First-Line Sunitinib(2012)